GBA1 and Parkinson disease: In addition to these in vitro studies, a recent study showed that total α‐synuclein levels were significantly higher in CSF samples from PD patients with severe GBA1 mutations compared to PD patients with mild or no GBA1 mutations (Lerche et al., 2020).